Log in

Relevant bibliographies by topics / Ebola Virus Infection / Journal articles

To see the other types of publications on this topic, follow the link: Ebola Virus Infection.

Journal articles on the topic 'Ebola Virus Infection'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ebola Virus Infection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

BOZKURT, İlkay, and Hakan LEBLEBİCİOĞLU. "Ebola Virus Infection." Mediterranean Journal of Infection Microbes and Antimicrobials 3, no. 1 (2014): 1–7. http://dx.doi.org/10.5578/mjima.8945.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Warfield, Kelly L., Jeremy G. Perkins, Dana L. Swenson, et al. "Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection." Journal of Experimental Medicine 200, no. 2 (2004): 169–79. http://dx.doi.org/10.1084/jem.20032141.

Full text

Abstract:

Ebola virus is a highly lethal human pathogen and is rapidly driving many wild primate populations toward extinction. Several lines of evidence suggest that innate, nonspecific host factors are potentially critical for survival after Ebola virus infection. Here, we show that nonreplicating Ebola virus-like particles (VLPs), containing the glycoprotein (GP) and matrix protein virus protein (VP)40, administered 1–3 d before Ebola virus infection rapidly induced protective immunity. VLP injection enhanced the numbers of natural killer (NK) cells in lymphoid tissues. In contrast to live Ebola viru

APA, Harvard, Vancouver, ISO, and other styles

3

MORIKAWA, Shigeru. "Ebola-Reston Virus Infection." Journal of Veterinary Epidemiology 14, no. 1 (2010): 76–77. http://dx.doi.org/10.2743/jve.14.76.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nabel, Gary J. "Surviving Ebola virus infection." Nature Medicine 5, no. 4 (1999): 373–74. http://dx.doi.org/10.1038/7363.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Warfield, Kelly L., Catharine M. Bosio, Brent C. Welcher, et al. "Ebola virus-like particles protect from lethal Ebola virus infection." Proceedings of the National Academy of Sciences of the United States of America 100, no. 26 (2003): 15889–94. https://doi.org/10.5281/zenodo.13536299.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) The filovirus Ebola causes hemorrhagic fever with 70-80% human mortality. High case-fatality rates, as well as known aerosol infectivity, make Ebola virus a potential global health threat and possible biological warfare agent. Development of an effective vaccine for use in natural outbreaks, response to biological attack, and protection of laboratory workers is a higher national priority than ever before. Coexpression of the Ebola virus glycoprotein (GP) and matrix protein (VP40) in mammalian cells results in spontaneous production and release

APA, Harvard, Vancouver, ISO, and other styles

6

Warfield, Kelly L., Catharine M. Bosio, Brent C. Welcher, et al. "Ebola virus-like particles protect from lethal Ebola virus infection." Proceedings of the National Academy of Sciences of the United States of America 100, no. 26 (2003): 15889–94. https://doi.org/10.5281/zenodo.13536299.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) The filovirus Ebola causes hemorrhagic fever with 70-80% human mortality. High case-fatality rates, as well as known aerosol infectivity, make Ebola virus a potential global health threat and possible biological warfare agent. Development of an effective vaccine for use in natural outbreaks, response to biological attack, and protection of laboratory workers is a higher national priority than ever before. Coexpression of the Ebola virus glycoprotein (GP) and matrix protein (VP40) in mammalian cells results in spontaneous production and release

APA, Harvard, Vancouver, ISO, and other styles

7

Sizikova, T. E., V. N. Lebedev, N. V. Karulina, O. V. Chukhralya, S. I. Syromyatnikova, and S. V. Borisevich. "A SOME ECOLOGICAL CHARACTERISTICS OF EBOLA VIRUS IN NATURAL FOCIES." Journal of microbiology epidemiology immunobiology, no. 2 (April 28, 2018): 119–26. http://dx.doi.org/10.36233/0372-9311-2018-2-119-126.

Full text

Abstract:

Ebola virus that composed Ebolavirus genus of Filoviridae Family causes severe hemorrhagic fever in humans with high case-fatality rates (up to 90%). The Ebolavirus genus includes Ebola-Zaire, Ebola-Sudan, Ebola-Reston, Ebola-Tai Forest and Ebola-Bundibugyo viruses. The date about epidemic outbreaks of disease, reservoirs of infection, accidental hosts of Ebola virus are presented in this review. The date about natural reservoirs of infection are accessed only for Ebola-Zaire and Ebola-Reston viruses. For Ebola-Sudan, Ebola-Tai Forest and Ebola-Bundibugyo viruses such information is absence. T

APA, Harvard, Vancouver, ISO, and other styles

8

Olinger, Gene G., Michael A. Bailey, John M. Dye, et al. "Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins." Journal of Virology 79, no. 22 (2005): 14189–96. http://dx.doi.org/10.1128/jvi.79.22.14189-14196.2005.

Full text

Abstract:

ABSTRACT Infection with Ebola virus causes a severe disease accompanied by high mortality rates, and there are no licensed vaccines or therapies available for human use. Filovirus vaccine research efforts still need to determine the roles of humoral and cell-mediated immune responses in protection from Ebola virus infection. Previous studies indicated that exposure to Ebola virus proteins expressed from packaged Venezuelan equine encephalitis virus replicons elicited protective immunity in mice and that antibody-mediated protection could only be demonstrated after vaccination against the glyco

APA, Harvard, Vancouver, ISO, and other styles

9

Warfield, K. L., C. M. Bosio, B. C. Welcher, et al. "Ebola virus-like particles protect from lethal Ebola virus infection." Proceedings of the National Academy of Sciences 100, no. 26 (2003): 15889–94. http://dx.doi.org/10.1073/pnas.2237038100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Reiter, Russel J., Qiang Ma, and Ramaswamy Sharma. "Treatment of ebola and other infectious diseases: melatonin “goes viral”." Melatonin Research 3, no. 1 (2020): 43–57. http://dx.doi.org/10.32794/mr11250047.

Full text

Abstract:

This review summarizes published reports on the utility of melatonin as a treatment for virus-mediated diseases. Of special note are the data related to the role of melatonin in influencing Ebola virus disease. This infection and deadly condition has no effective treatment and the published works documenting the ability of melatonin to attenuate the severity of viral infections generally and Ebola infection specifically are considered. The capacity of melatonin to prevent one of the major complications of an Ebola infection, i.e., the hemorrhagic shock syndrome, which often contributes to the

APA, Harvard, Vancouver, ISO, and other styles

11

Kaletsky, Rachel L., Graham Simmons, and Paul Bates. "Proteolysis of the Ebola Virus Glycoproteins Enhances Virus Binding and Infectivity." Journal of Virology 81, no. 24 (2007): 13378–84. http://dx.doi.org/10.1128/jvi.01170-07.

Full text

Abstract:

ABSTRACT Cellular cathepsins are required for Ebola virus infection and are believed to proteolytically process the Ebola virus glycoprotein (GP) during entry. However, the significance of cathepsin cleavage during infection remains unclear. Here we demonstrate a role for cathepsin L (CatL) cleavage of Ebola virus GP in the generation of a stable 18-kDa GP1 viral intermediate that exhibits increased binding to and infectivity for susceptible cell targets. Cell binding to a lymphocyte line was increased when CatL-proteolysed pseudovirions were used, but lymphocytes remained resistant to Ebola v

APA, Harvard, Vancouver, ISO, and other styles

12

Gupta, Manisha, Siddhartha Mahanty, Mike Bray, Rafi Ahmed, and Pierre E. Rollin. "Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication." Journal of Virology 75, no. 10 (2001): 4649–54. http://dx.doi.org/10.1128/jvi.75.10.4649-4654.2001.

Full text

Abstract:

ABSTRACT Ebola hemorrhagic fever is a severe, usually fatal illness caused by Ebola virus, a member of the filovirus family. The use of nonhomologous immune serum in animal studies and blood from survivors in two anecdotal reports of Ebola hemorrhagic fever in humans has shown promise, but the efficacy of these treatments has not been demonstrated definitively. We have evaluated the protective efficacy of polyclonal immune serum in a mouse model of Ebola virus infection. Our results demonstrate that mice infected subcutaneously with live Ebola virus survive infection and generate high levels o

APA, Harvard, Vancouver, ISO, and other styles

13

Leroy, E. M., P. Telfer, B. Kumulungui, et al. "A serological survey of Ebola virus infection in central African nonhuman primates." Journal of infectious diseases 190, no. 11 (2004): 1895–99. https://doi.org/10.5281/zenodo.13537954.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) We used an ELISA to determine the prevalence of IgG antibodies specific for the Zaire subtype of Ebola virus in 790 nonhuman primates, belonging to 20 species, studied between 1985 and 2000 in Cameroon, Gabon, and the Republic of Congo. The seroprevalence rate of Ebola antibody in wild-born chimpanzees was 12.9%, indicating that (1) Ebola virus circulates in the forests of a large region of central Africa, including countries such as Cameroon, where no human cases of Ebola infections have been reported; (2) Ebola virus was present in the area

APA, Harvard, Vancouver, ISO, and other styles

14

Leroy, E. M., P. Telfer, B. Kumulungui, et al. "A serological survey of Ebola virus infection in central African nonhuman primates." Journal of infectious diseases 190, no. 11 (2004): 1895–99. https://doi.org/10.5281/zenodo.13537954.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) We used an ELISA to determine the prevalence of IgG antibodies specific for the Zaire subtype of Ebola virus in 790 nonhuman primates, belonging to 20 species, studied between 1985 and 2000 in Cameroon, Gabon, and the Republic of Congo. The seroprevalence rate of Ebola antibody in wild-born chimpanzees was 12.9%, indicating that (1) Ebola virus circulates in the forests of a large region of central Africa, including countries such as Cameroon, where no human cases of Ebola infections have been reported; (2) Ebola virus was present in the area

APA, Harvard, Vancouver, ISO, and other styles

15

Mbala, Placide, Marc Baguelin, Ipos Ngay, et al. "Evaluating the frequency of asymptomatic Ebola virus infection." Philosophical Transactions of the Royal Society B: Biological Sciences 372, no. 1721 (2017): 20160303. http://dx.doi.org/10.1098/rstb.2016.0303.

Full text

Abstract:

The potential for asymptomatic infection from Ebola viruses has long been questioned. Knowing the proportion of infections that are asymptomatic substantially changes the predictions made by mathematical models and alters the corresponding decisions based upon these models. To assess the degree of asymptomatic infection occurring during an Ebola virus disease (EVD) outbreak, we carried out a serological survey in the Djera district of the Equateur province of the Democratic Republic of the Congo affected by an Ebola outbreak in 2014. We sampled all asymptomatic residents ( n = 182) of 48 house

APA, Harvard, Vancouver, ISO, and other styles

16

Kim, Min Ji, Hui Young Kim, Soung Min Kim, Hoon Myoung, and Jong Ho Lee. "Systemic and oral manifestations of Ebola virus disease." Journal of The Korean Dental Association 54, no. 1 (2016): 67–83. http://dx.doi.org/10.22974/jkda.2015.54.1.008.

Full text

Abstract:

Ebola virus disease is a lethal viral hemorrhagic fever that has been boiling in sub-Saharan Africa since 1970s. Last year, The Ebola virus epidemic that has spread not only mainly in West Africa, but also in locals such as USA, Europe and the Antipodes via infected travelers, was brought up. Human-to-human transmission of Ebola virus disease is known only through direct contact with the blood, secretions, tissues or other bodily fluids, including saliva. Although there has not been reported infection cases in the dental healthcare settings, the fact that the infection of the Ebola virus may b

APA, Harvard, Vancouver, ISO, and other styles

17

Takada, Ayato, Heinz Feldmann, Thomas G. Ksiazek, and Yoshihiro Kawaoka. "Antibody-Dependent Enhancement of Ebola Virus Infection." Journal of Virology 77, no. 13 (2003): 7539–44. http://dx.doi.org/10.1128/jvi.77.13.7539-7544.2003.

Full text

Abstract:

ABSTRACT Most strains of Ebola virus cause a rapidly fatal hemorrhagic disease in humans, yet there are still no biologic explanations that adequately account for the extreme virulence of these emerging pathogens. Here we show that Ebola Zaire virus infection in humans induces antibodies that enhance viral infectivity. Plasma or serum from convalescing patients enhanced the infection of primate kidney cells by the Zaire virus, and this enhancement was mediated by antibodies to the viral glycoprotein and by complement component C1q. Our results suggest a novel mechanism of antibody-dependent en

APA, Harvard, Vancouver, ISO, and other styles

18

Samaranayake, L. P., J. S. Peiris, and C. Scully. "Ebola virus infection: an overview." British Dental Journal 180, no. 7 (1996): 264–66. http://dx.doi.org/10.1038/sj.bdj.4809048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Xu, Ling, Anthony Sanchez, Zhi-Yong Yang, et al. "Immunization for Ebola virus infection." Nature Medicine 4, no. 1 (1998): 37–42. http://dx.doi.org/10.1038/nm0198-037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Baxter, Alan G. "Symptomless infection with Ebola virus." Lancet 355, no. 9222 (2000): 2178–79. http://dx.doi.org/10.1016/s0140-6736(00)02394-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Rios-González, Carlos Miguel, and Ginno Alessandro De Benedictis-Serrano. "Reflections on Ebola virus infection." Asian Pacific Journal of Tropical Disease 7, no. 12 (2017): 811–12. http://dx.doi.org/10.12980/apjtd.7.2017d7-203.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Wool-Lewis, Rouven J., and Paul Bates. "Characterization of Ebola Virus Entry by Using Pseudotyped Viruses: Identification of Receptor-Deficient Cell Lines." Journal of Virology 72, no. 4 (1998): 3155–60. http://dx.doi.org/10.1128/jvi.72.4.3155-3160.1998.

Full text

Abstract:

ABSTRACT Studies analyzing Ebola virus replication have been severely hampered by the extreme pathogenicity of this virus. To permit analysis of the host range and function of the Ebola virus glycoprotein (Ebo-GP), we have developed a system for pseudotyping these glycoproteins into murine leukemia virus (MLV). This pseudotyped virus, MLV(Ebola), can be readily concentrated to titers which exceed 5 × 106 infectious units/ml and is effectively neutralized by antibodies specific for Ebo-GP. Analysis of MLV(Ebola) infection revealed that the host range conferred by Ebo-GP is very broad, extending

APA, Harvard, Vancouver, ISO, and other styles

23

Schwartz, David. "Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should Have Been) Learned from Excluding Immunization with the Ebola Vaccine during Pregnancy and Lactation." Vaccines 6, no. 4 (2018): 81. http://dx.doi.org/10.3390/vaccines6040081.

Full text

Abstract:

As evidenced from recent epidemics, both Ebola and Zika virus infection are potentially catastrophic when occurring in pregnant women. Ebola virus causes extremely high rates of mortality in both mothers and infants; Zika virus is a TORCH infection that produces a congenital malformation syndrome and pediatric neurodevelopmental abnormalities. Production of efficacious vaccines has been a public health priority for both infections. Unfortunately, during the clinical trials and subsequent deployment of a vaccine for the Ebola virus, pregnant and lactating women were, and continue to be, exclude

APA, Harvard, Vancouver, ISO, and other styles

24

Okumura, Atsushi, Paula M. Pitha, Akihiko Yoshimura, and Ronald N. Harty. "Interaction between Ebola Virus Glycoprotein and Host Toll-Like Receptor 4 Leads to Induction of Proinflammatory Cytokines and SOCS1." Journal of Virology 84, no. 1 (2009): 27–33. http://dx.doi.org/10.1128/jvi.01462-09.

Full text

Abstract:

ABSTRACT Ebola virus initially targets monocytes and macrophages, which can lead to the release of proinflammatory cytokines and chemokines. These inflammatory cytokines are thought to contribute to the development of circulatory shock seen in fatal Ebola virus infections. Here we report that host Toll-like receptor 4 (TLR4) is a sensor for Ebola virus glycoprotein (GP) on virus-like particles (VLPs) and that resultant TLR4 signaling pathways lead to the production of proinflammatory cytokines and suppressor of cytokine signaling 1 (SOCS1) in a human monocytic cell line and in HEK293-TLR4/MD2

APA, Harvard, Vancouver, ISO, and other styles

25

Haque, Azizul, Didier Hober, and Joel Blondiaux. "Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks." Antimicrobial Agents and Chemotherapy 59, no. 10 (2015): 5892–902. http://dx.doi.org/10.1128/aac.01105-15.

Full text

Abstract:

ABSTRACTEbola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre- and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studi

APA, Harvard, Vancouver, ISO, and other styles

26

Kraft, Colleen S., Aneesh K. Mehta, Jay B. Varkey, et al. "Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States." Infection Control & Hospital Epidemiology 41, no. 4 (2020): 385–90. http://dx.doi.org/10.1017/ice.2019.349.

Full text

Abstract:

AbstractObjective:Healthcare personnel (HCP) were recruited to provide serum samples, which were tested for antibodies against Ebola or Lassa virus to evaluate for asymptomatic seroconversion.Setting:From 2014 to 2016, 4 patients with Ebola virus disease (EVD) and 1 patient with Lassa fever (LF) were treated in the Serious Communicable Diseases Unit (SCDU) at Emory University Hospital. Strict infection control and clinical biosafety practices were implemented to prevent nosocomial transmission of EVD or LF to HCP.Participants:All personnel who entered the SCDU who were required to measure thei

APA, Harvard, Vancouver, ISO, and other styles

27

Wang, Leah Liu, Kendra Alfson, Brett Eaton, et al. "Algal Lectin Griffithsin Inhibits Ebola Virus Infection." Molecules 30, no. 4 (2025): 892. https://doi.org/10.3390/molecules30040892.

Full text

Abstract:

Algal lectin Griffithsin (GRFT) is a well-known mannose-binding protein which has broad-spectrum antiviral activity against several important infectious viruses including HIV, HCV, and SARS-CoV-2. Therefore, GRFT has been brought great attention to antiviral therapeutic development. In this report, we have tested GRFT’s activity against the lethal Ebola virus in vitro and in vivo. Our data have shown that the IC50 value is about 42 nM for inhibiting Zaire Ebola virus (EBOV) infection in vitro. The preliminary in vivo mice model using mouse-adapted EBOV has also shown a certain efficacy for del

APA, Harvard, Vancouver, ISO, and other styles

28

Knežević, Darija, and Duška Jović. "Ebola 2014 - unprecedented epidemic / Ebola 2014 – epidemija bez presedana." SESTRINSKI ŽURNAL 2, no. 2 (2015): 11. http://dx.doi.org/10.7251/sez0215011k.

Full text

Abstract:

Ebola, previously known as Ebola hemorrhagic fever, is a rare and deadly disease caused by infection with one of the Ebola virus strains. Starting from February 2014, the Ebola virus outbreak had spread across West African countries within a few months and caused great concerns of the World Health Organization. Currently there are no effective vaccines and drugs that are available for the prevention and treatment of infection with Ebola virus. Medical personnel caring for patients with suspect or confirmed Ebola viral disease is particularly exposed to the risk of suffering from this dangerous

APA, Harvard, Vancouver, ISO, and other styles

29

Alvarez, Carmen P., Fátima Lasala, Jaime Carrillo, Oscar Muñiz, Angel L. Corbí, and Rafael Delgado. "C-Type Lectins DC-SIGN and L-SIGN Mediate Cellular Entry by Ebola Virus in cis and in trans." Journal of Virology 76, no. 13 (2002): 6841–44. http://dx.doi.org/10.1128/jvi.76.13.6841-6844.2002.

Full text

Abstract:

ABSTRACT Ebola virus is a highly lethal pathogen responsible for several outbreaks of hemorrhagic fever. Here we show that the primate lentiviral binding C-type lectins DC-SIGN and L-SIGN act as cofactors for cellular entry by Ebola virus. Furthermore, DC-SIGN on the surface of dendritic cells is able to function as a trans receptor, binding Ebola virus-pseudotyped lentiviral particles and transmitting infection to susceptible cells. Our data underscore a role for DC-SIGN and L-SIGN in the infective process and pathogenicity of Ebola virus infection.

APA, Harvard, Vancouver, ISO, and other styles

30

Liao, Laura E., Jonathan Carruthers, Sophie J. Smither, et al. "Quantification of Ebola virus replication kinetics in vitro." PLOS Computational Biology 16, no. 11 (2020): e1008375. http://dx.doi.org/10.1371/journal.pcbi.1008375.

Full text

Abstract:

Mathematical modelling has successfully been used to provide quantitative descriptions of many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities for experimentation, modelling can play a crucial role. Ebola virus modelling efforts have primarily focused on in vivo virus kinetics, e.g., in animal models, to aid the development of antivirals and vaccines. But, thus far, these studies have not yielded a detailed specification of the infection cycle, which could provide a foundational description of the virus kinetics and thus a deeper understanding of their cl

APA, Harvard, Vancouver, ISO, and other styles

31

Anantpadma, Manu, Jennifer Kouznetsova, Hang Wang, et al. "Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors." Antimicrobial Agents and Chemotherapy 60, no. 8 (2016): 4471–81. http://dx.doi.org/10.1128/aac.00543-16.

Full text

Abstract:

ABSTRACTFiloviruses are highly infectious, and no FDA-approved drug therapy for filovirus infection is available. Most work to find a treatment has involved only a few strains of Ebola virus and testing of relatively small drug libraries or compounds that have shown efficacy against other virus types. Here we report the findings of a high-throughput screening of 319,855 small molecules from the Molecular Libraries Small Molecule Repository library for their activities against Marburg virus and Ebola virus. Nine of the most potent, novel compounds that blocked infection by both viruses were ana

APA, Harvard, Vancouver, ISO, and other styles

32

McElroy, Anita K., Rama S. Akondy, Carl W. Davis, et al. "Human Ebola virus infection results in substantial immune activation." Proceedings of the National Academy of Sciences 112, no. 15 (2015): 4719–24. http://dx.doi.org/10.1073/pnas.1502619112.

Full text

Abstract:

Four Ebola patients received care at Emory University Hospital, presenting a unique opportunity to examine the cellular immune responses during acute Ebola virus infection. We found striking activation of both B and T cells in all four patients. Plasmablast frequencies were 10–50% of B cells, compared with less than 1% in healthy individuals. Many of these proliferating plasmablasts were IgG-positive, and this finding coincided with the presence of Ebola virus-specific IgG in the serum. Activated CD4 T cells ranged from 5 to 30%, compared with 1–2% in healthy controls. The most pronounced resp

APA, Harvard, Vancouver, ISO, and other styles

33

Wang, Yunpeng, and Yuchen Zhang. "Research progress Ebola Hemorrhagic Fever vaccine." Journal of Applied Virology 4, no. 2 (2015): 37. http://dx.doi.org/10.21092/jav.v4i2.32.

Full text

Abstract:

<p>Ebola hemorrhagic fever is a potent infectious disease by Ebola virus caused 90% mortality rate. Ebola virus was first isolated in 1976 by, for single-stranded negative segment, non-segmented, enveloped RNA viruses belonging to filamentous virus family. Ebola virus can be divided into five different subtypes. Vaccination is the most conventional and effective prevention and infection control methods in recent years. It has made great progress in the study on the vaccine for Ebola virus. In this paper, research progress Ebola hemorrhagic fever vaccine was reviewed.</p>

APA, Harvard, Vancouver, ISO, and other styles

34

Favier, Anne-Laure, Olivier Reynard, Evelyne Gout, et al. "Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction." Viruses 11, no. 1 (2018): 15. http://dx.doi.org/10.3390/v11010015.

Full text

Abstract:

Since the largest 2014–2016 Ebola virus disease outbreak in West Africa, understanding of Ebola virus infection has improved, notably the involvement of innate immune mediators. Amongst them, collectins are important players in the antiviral innate immune defense. A screening of Ebola glycoprotein (GP)-collectins interactions revealed the specific interaction of human surfactant protein D (hSP-D), a lectin expressed in lung and liver, two compartments where Ebola was found in vivo. Further analyses have demonstrated an involvement of hSP-D in the enhancement of virus infection in several in vi

APA, Harvard, Vancouver, ISO, and other styles

35

Ahmed, Mejbah Uddin, and Sushmita Roy. "Ebola Virus ? A Global Threat." Journal of Enam Medical College 5, no. 1 (2015): 44–51. http://dx.doi.org/10.3329/jemc.v5i1.21497.

Full text

Abstract:

Ebola virus is a filamentous, enveloped, non-segmented, single-stranded, negative-sense RNA virus. It belongs to the Filoviridae and was first recognized near the Ebola River valley in Zaire in 1976. Since then most of the outbreaks have occurred to both human and nonhuman primates in sub-Saharan Africa. Ebola virus causes highly fatal hemorrhagic fever in human and nonhuman primates. In addition to hemorrhagic fever, it could be used as a bioterrorism agent. Although its natural reservoir is yet to be proven, current data suggest that fruit bats are the possibility. Infection has also been do

APA, Harvard, Vancouver, ISO, and other styles

36

Collados Rodríguez, Mila, Patrick Maillard, Alexandra Journeaux, et al. "Novel Antiviral Molecules against Ebola Virus Infection." International Journal of Molecular Sciences 24, no. 19 (2023): 14791. http://dx.doi.org/10.3390/ijms241914791.

Full text

Abstract:

Infection with Ebola virus (EBOV) is responsible for hemorrhagic fever in humans with a high mortality rate. Combined efforts of prevention and therapeutic intervention are required to tackle highly variable RNA viruses, whose infections often lead to outbreaks. Here, we have screened the 2P2I3D chemical library using a nanoluciferase-based protein complementation assay (NPCA) and isolated two compounds that disrupt the interaction of the EBOV protein fragment VP35IID with the N-terminus of the dsRNA-binding proteins PKR and PACT, involved in IFN response and/or intrinsic immunity, respectivel

APA, Harvard, Vancouver, ISO, and other styles

37

Pan, Zhi-Yong, Yan-Jun Wu, Ye-Xian Zeng, et al. "Pooled Analysis of the Accuracy of Xpert Ebola Assay for Diagnosing Ebola Virus Infection." BioMed Research International 2021 (May 17, 2021): 1–8. http://dx.doi.org/10.1155/2021/5527505.

Full text

Abstract:

Background. West Africa has witnessed the unprecedented outbreak of Ebola virus disease (EVD). The Ebola virus (EBOV) can cause Ebola hemorrhagic fever, which is documented as the most deadly viral hemorrhagic fever in the world. RT-PCR had been suggested to be employed in the detection of Ebola virus; however, this method has high requirements for laboratory equipment and takes a long time to determine Ebola infection. Although Xpert Ebola is a fast and simple instrument for the detection of Ebola virus, its effect is still unclear. This study is aimed at evaluating the accuracy of Xpert Ebol

APA, Harvard, Vancouver, ISO, and other styles

38

Judson, Seth D., Robert Fischer, Andrew Judson, and Vincent J. Munster. "Ecological Contexts of Index Cases and Spillover Events of Different Ebolaviruses." PLOS Pathogens 12, no. 8 (2016): e1005780. https://doi.org/10.5281/zenodo.13536047.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) Ebola virus disease afflicts both human and animal populations and is caused by four ebolaviruses. These different ebolaviruses may have distinct reservoir hosts and ecological contexts that determine how, where, and when different ebolavirus spillover events occur. Understanding these virus-specific relationships is important for preventing transmission of ebolaviruses from wildlife to humans. We examine the ecological contexts surrounding 34 human index case infections of ebolaviruses from 1976–2014. Determining possible sources of spillover

APA, Harvard, Vancouver, ISO, and other styles

39

Judson, Seth D., Robert Fischer, Andrew Judson, and Vincent J. Munster. "Ecological Contexts of Index Cases and Spillover Events of Different Ebolaviruses." PLOS Pathogens 12, no. 8 (2016): e1005780. https://doi.org/10.5281/zenodo.13536047.

Full text

Abstract:

(Uploaded by Plazi for the Bat Literature Project) Ebola virus disease afflicts both human and animal populations and is caused by four ebolaviruses. These different ebolaviruses may have distinct reservoir hosts and ecological contexts that determine how, where, and when different ebolavirus spillover events occur. Understanding these virus-specific relationships is important for preventing transmission of ebolaviruses from wildlife to humans. We examine the ecological contexts surrounding 34 human index case infections of ebolaviruses from 1976–2014. Determining possible sources of spillover

APA, Harvard, Vancouver, ISO, and other styles

40

Y, Nesradin. "Ebola Virus and its Public Health Significance: A Review." Open Access Journal of Veterinary Science & Research 3, no. 3 (2018): 1–10. http://dx.doi.org/10.23880/oajvsr-16000165.

Full text

Abstract:

Ebola virus disease is a severe, often - fatal, zoonotic viral disease in humans and Nonhuman primates (NHP) like monkeys, gorillas and chimpanzees. Ebola is RNA virus that belongs to the family filoviridae, genus Ebola virus. The viruses (EBOV) are enveloped, non - segmented, negative - sense, single - stranded RNA viruses. Ebola virus disease (EVD) was first described in the Democratic Republic of Congo (DRC) in 1976. The exact origin, locations and natural reservoir of Ebola virus remain unclear. People can be exposed to Ebola virus from direct contact with the blood and/or secretions of an

APA, Harvard, Vancouver, ISO, and other styles

41

Golkar, Zhabiz, Roshan Battaria, Donald G. Pace, and Omar Bagasra. "Inhibition of Ebola Virus by Anti-Ebola miRNAs in silico." Journal of Infection in Developing Countries 10, no. 06 (2016): 626–34. http://dx.doi.org/10.3855/jidc.7127.

Full text

Abstract:

Introduction: MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate transcriptional and posttranscriptional gene regulation of the organisms. miRNA provides immune defense when the body is faced with challenges intracellular agents. miRNA molecules trigger gene silencing in eukaryotic cells. More than 3,000 different human miRNAs (hsa-miRs) have been identified thus far. During ontogenesis, viral or intracellular parasitic infections, miRNAs are differentially expressed to protect the host from intracellular invaders. In a viral infection context, miRNAs have been connected with

APA, Harvard, Vancouver, ISO, and other styles

42

Liu, Ching-Hsuan, Yee-Tung Hu, Shu Hui Wong, and Liang-Tzung Lin. "Therapeutic Strategies against Ebola Virus Infection." Viruses 14, no. 3 (2022): 579. http://dx.doi.org/10.3390/v14030579.

Full text

Abstract:

Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and has become a major threat to global health. EBOV is a risk group 4 pathogen, which imposes significant obstacles for the development of countermeasures against the virus. Efforts have been made to develop anti-EBOV immunization and therapeutics, with three vaccines and two antibody-based therapeutics approved in recent years. Nonetheless, the high fatality of Ebola virus disease highlights the need to continuously develop antiviral strategies for the future management of EBOV outbreaks in conjunction with vacc

APA, Harvard, Vancouver, ISO, and other styles

43

Rhein, Bethany A., Linda S. Powers, Kai Rogers та ін. "Interferon-γ Inhibits Ebola Virus Infection". PLOS Pathogens 11, № 11 (2015): e1005263. http://dx.doi.org/10.1371/journal.ppat.1005263.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Billioux, Bridgette Jeanne, Bryan Smith, and Avindra Nath. "Neurological Complications of Ebola Virus Infection." Neurotherapeutics 13, no. 3 (2016): 461–70. http://dx.doi.org/10.1007/s13311-016-0457-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

McElroy, Anita K., Elke Mühlberger, and César Muñoz-Fontela. "Immune barriers of Ebola virus infection." Current Opinion in Virology 28 (February 2018): 152–60. http://dx.doi.org/10.1016/j.coviro.2018.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

De Clercq, Erik. "Ebola virus (EBOV) infection: Therapeutic strategies." Biochemical Pharmacology 93, no. 1 (2015): 1–10. http://dx.doi.org/10.1016/j.bcp.2014.11.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Drancourt, Michel, and Didier Raoult. "Malaria Therapy for Ebola Virus Infection." Clinical Infectious Diseases 64, no. 5 (2017): 696–97. http://dx.doi.org/10.1093/cid/ciw821.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Xu, Mary Jue, Gaelen Stanford-Moore, and Josephine A. Czechowicz. "Association of Ebola Virus Infection With Hearing Loss in Regions Where Ebola Virus Infection Is Endemic." JAMA Otolaryngology–Head & Neck Surgery 145, no. 7 (2019): 669. http://dx.doi.org/10.1001/jamaoto.2019.0710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wilson, Julie A., and Mary Kate Hart. "Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein." Journal of Virology 75, no. 6 (2001): 2660–64. http://dx.doi.org/10.1128/jvi.75.6.2660-2664.2001.

Full text

Abstract:

ABSTRACT Cytotoxic T lymphocytes (CTLs) are proposed to be critical for protection from intracellular pathogens such as Ebola virus. However, there have been no demonstrations that protection against Ebola virus is mediated by Ebola virus-specific CTLs. Here, we report that C57BL/6 mice vaccinated with Venezuelan equine encephalitis virus replicons encoding the Ebola virus nucleoprotein (NP) survived lethal challenge with Ebola virus. Vaccination induced both antibodies to the NP and a major histocompatibility complex class I-restricted CTL response to an 11-amino-acid sequence in the amino-te

APA, Harvard, Vancouver, ISO, and other styles

50

Yanti, Henny Elfira, and Aryati Aryati. "PENYAKIT VIRUS EBOLA." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 21, no. 2 (2018): 195. http://dx.doi.org/10.24293/ijcpml.v21i2.1108.

Full text

Abstract:

Ebola virus disease has known as Ebola hemorrhagic fever (EHF) is an acute viral syndrome characterized by fever and bleeding witha high mortality rate in humans and non human (primates). The current outbreak inWestern Africa is the largest ebola outbreak since theebola virus was first discovered in 1976. The first EHF case that reemerged back in Africa occurred in March 2014 and in Desember 29th2014 had been revealed 20,153 cases and 7,883 deaths. The virus is transmitted from wild animals and spread in the human populationthrough human –to -human transmission. Ebola virus infection is charac

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!